Search

Displaying results 2421 - 2430 of 6835 in total
  1. Drug

    Icosapent ethyl

    go.drugbank.com/drugs/DB08887
    ApprovedInvestigationalNutraceutical

    It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.

  2. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    [A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred … in pregnancy due to a perceived lower risk of teratogenic effects.

  3. Drug

    Flucytosine

    go.drugbank.com/drugs/DB01099
    ApprovedInvestigational

    A fluorinated cytosine analog that is used as an antifungal agent.

  4. Drug

    Aluminum chloride

    go.drugbank.com/drugs/DB11081
    ApprovedInvestigational

    When contaminated with iron chloride, it often displays a yellow color compared to the white pure compound. … In antiperspirant products, FDA approves the use of aluminum chloride as an active ingredient up to 15%, calculated on the hexahydrate form, in an aqueous solution nonaerosol dosage form [L2012].

  5. Drug

    Itraconazole

    go.drugbank.com/drugs/DB01167
    ApprovedInvestigational

    First synthesized in the early 1980s, itraconazole is a broad-spectrum triazole antifungal agent used to treat a variety of infections. … [A34257] It is a 1:1:1:1 racemic mixture of four diastereomers, made up of two enantiomeric pairs, each possessing three chiral centers.

  6. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    [A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. … [A7056] Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].

  7. Drug

    Sulindac

    go.drugbank.com/drugs/DB00605
    ApprovedInvestigational

    Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. … While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.

  8. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses. … It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis.

  9. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    [A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma

  10. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    [L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

    Synonyms: Co-ArgI-PEG, Co-ArgI-PEG modified human arginase I